Get the Stockscreener App
10.94
2.15%
0.23
Roivant Sciences Ltd stock is traded at $10.94, with a volume of 15.61M.
It is up +2.15% in the last 24 hours and up +2.53% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$10.71
Open:
$10.55
24h Volume:
15.61M
Relative Volume:
3.37
Market Cap:
$7.81B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.9363
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+3.21%
1M Performance:
+2.53%
6M Performance:
-8.22%
1Y Performance:
+10.17%
1-Day Range:
$10.55
$11.41
1-Week Range:
$10.40
$11.41
52-Week Range:
$9.80
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.94 | 7.81B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - Scrip
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
(ROIV) Trading Signals - Stock Traders Daily
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Trend Tracker for (ROIV) - Stock Traders Daily
Principal Financial Group Inc. Lowers Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Handelsbanken Fonder AB Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Net worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governor - The Times of India
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - The Manila Times
Early Warning Report Issued Pursuant to National Instrument 62?103: Roivant announces Resignation and Replacement of Arbutus Board - Lelezard
Roivant Sciences president Eric Venker sells $1.07 million in shares - Investing.com India
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat
Long Term Trading Analysis for (ROIV) - Stock Traders Daily
Roivant Sciences’ chief accounting officer sells $2.37 million in shares - Investing.com India
Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada
Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up After Earnings Beat - MarketBeat
178,853 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Elevate Capital Advisors LLC - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Roivant Sciences: Earnings Reveal Strategic Clinical Advances - MSN
Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position - MSN
Roivant Sciences price target lowered to $12 from $13 at BofA - Yahoo Finance
Roivant Sciences Ltd. (ROIV): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Roivant Sciences Insiders Sold US$52m Of Shares Suggesting Hesitancy - Simply Wall St
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):